Statutory & financial benchmarks
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Legal origin | Section 503A, added by the Food and Drug Administration Modernization Act of 1997 | Section 503B, added by the Drug Quality and Security Act of 2013 |
| Primary regulator | State board of pharmacy | FDA (registration, inspection), plus state licensure where the state requires it |
| Prescription requirement | Valid prescription for an identified individual patient (limited anticipatory compounding based on history) | Not required; may supply facilities for office use |
| Manufacturing standard | USP chapters (<797> for sterile); exempt from cGMP | Current good manufacturing practice, with FDA inspections on a risk basis |
| Registration and reporting | State licence; nonresident licences to ship into other states | Annual FDA registration and fee; product reports to FDA twice a year; adverse event reporting |
| Labeling | Patient name and prescription label | Identifies the product as compounded, with facility, lot and BUD or expiry; office-use labeling when not patient-specific |
| Bulk drug substances | USP/NF monograph substances, components of approved drugs, or the 503A bulks list | Substances on the 503B bulks list or used to compound drugs on FDA’s shortage list |
| Copies of approved drugs | Not regularly or in inordinate amounts | Not essentially copies, unless the drug is in shortage |
| Fit for an IV hydration practice | Individual patients with documented needs | Clinic and mobile office stock, premixed multi-ingredient bags |
Why sourcing is a legal question, not a purchasing one
Most IV practices want the same thing: a shelf of vials and premixed bags they can use for whichever client books next. Federal law allows that only for certain products. FDA-approved drugs bought through licensed distributors can be stocked. Compounded drugs can be stocked only if they come from a 503B outsourcing facility; compounded drugs from a 503A pharmacy are made for a named patient and cannot lawfully be pooled into general clinic inventory.
The distinction exists because of failures. The 2012 fungal meningitis outbreak traced to contaminated steroid injections from a compounding pharmacy led Congress to pass the Drug Quality and Security Act in 2013, creating the 503B category with cGMP and FDA oversight. Boards and FDA investigators now treat clinic stock of non-patient-specific 503A products as a red flag.
Which supplier for which product
Start with the least compounded option that meets the clinical need. Many IV ingredients exist as FDA-approved products: 0.9% sodium chloride and Lactated Ringer’s, magnesium sulfate, calcium gluconate, cyanocobalamin, ondansetron, ketorolac and others. Ascorbic acid injection also has an FDA-approved product. Approved products come with labeling, established expiry dating and a manufacturer accountable for quality.
| Need | Best source | Why |
|---|---|---|
| Carrier fluids, single-agent vials that exist as approved products | FDA-approved manufacturer via licensed distributor | Approved labeling, longest dating, no compounding issues |
| Multi-ingredient premixed bags (Myers’-style, recovery, immune) | 503B outsourcing facility | Avoids exceeding USP <797> immediate-use limits in the clinic |
| Preservative-free or unusual strengths for office stock | 503B outsourcing facility | Office use allowed without patient names |
| A preparation tailored to one patient (allergy to an excipient, unusual dose) | 503A pharmacy with a patient-specific prescription | Designed for individualized compounding |
| Non-monograph ingredients such as NAD+ or glutathione | Supplier that can document the bulk substance’s regulatory status | Bulk substance categories under 503A and 503B have been under FDA review; confirm current status before ordering |
Some states permit limited office-use compounding by 503A pharmacies under state law. That does not change the federal conditions in section 503A, so ask counsel before relying on it.
How to vet a 503B outsourcing facility
Registration is the floor, not proof of quality. Before the first order, work through this list and keep the evidence in your compliance file.
- FDA registration: confirm the facility appears on FDA’s published list of registered human drug compounding outsourcing facilities.
- Inspection history: search FDA’s records for Form 483 observations, warning letters and recalls involving the facility.
- State licensure: many states require a nonresident outsourcing facility licence or registration before a 503B can ship in.
- Distribution channel: section 503B restricts resale of outsourcing facility products by entities other than the facility, so buy direct or confirm the channel is permissible.
- Stability support: BUDs or expiry dates should be backed by stability data, not assigned by default.
- Recall and complaint process: a named contact, a written recall procedure and lot-level traceability.
Reading a certificate of analysis
A certificate of analysis (CoA) is the lot-level report that shows the product met its release specifications. Ask for it with every new product and periodically for repeat lots.
| CoA element | What to look for | Red flag |
|---|---|---|
| Product identity and strength (potency/assay) | Result within the stated specification range | Result missing, or “conforms” with no number |
| Sterility testing | Method stated (USP <71> or a validated alternative) and a pass result | No sterility test for an aseptically filled lot |
| Bacterial endotoxins | Tested per USP <85>, result below the limit for the dose and route | No endotoxin result for an injectable |
| Particulate matter and appearance | Meets the applicable specification | Visible particles noted but released |
| Container closure and fill | Volume and integrity data where relevant | Inconsistent fill volumes across lots |
| Lot number and BUD | Matches the label on the vials you received | Mismatch between CoA and product label |
Fitting sourcing into daily operations
A sound purchasing workflow ties each vial on the shelf to an invoice, a lot and a CoA. Receive deliveries against the packing list, check temperature indicators for cold-chain products, record lot numbers and BUDs in your inventory system, and quarantine anything that arrives damaged or warm.
Use 503B premixed bags to stay inside USP <797> immediate-use limits, and keep patient-specific 503A products physically separated and labeled with the patient’s name so they cannot drift into general stock. Read the full immediate-use rules in USP <797> compliance for IV clinics and storage guidance in cold chain and mobile storage.
Supply cost per drip typically runs $28–$55 including carrier fluid, tubing, start kit and sterile product; 503B premixes sit at the upper end. Model your margin in the provider calculator, or request a vetted 503B introduction through the partner intake.
Step-by-step sterile sourcing setup
- Map the formularyFor each drip ingredient, note whether an FDA-approved product exists or a compounded one is needed.
- Prefer approved productsSource approved carrier fluids and single-agent vials through a licensed distributor.
- Shortlist 503B facilitiesConfirm each appears on FDA’s outsourcing facility list and holds any licence your state requires.
- Review inspection historyCheck Form 483s, warning letters and recalls; ask the facility how each was resolved.
- Request CoAs and stability supportObtain sample CoAs showing potency, sterility and endotoxin results, plus the basis for BUDs.
- Open the account correctlyUnder the clinical entity, with the medical director or prescriber as sponsor.
- Separate patient-specific stockStore 503A products by patient name, apart from office stock.
- Receive and log every deliveryCheck temperature indicators, record lot and BUD, file the CoA.
- Monitor recalls and shortagesSubscribe to FDA recall alerts and supplier notices; have a substitute plan for each ingredient.
Common regulatory audit traps
Office stock from a 503A pharmacy
Clinics that order compounded vials without patient names, or under one patient’s name for many clients, are a common inspection finding. Use a 503B facility for anything stocked for future patients.
Assuming registration means quality
An outsourcing facility can be registered and still have open warning letters. Check inspection history and request CoAs before ordering.
Research-grade ingredients
NAD+, peptides and amino acids sold for research are not for human use and have no sterility assurance. Buy only from licensed, FDA-registered sources with documented bulk substance status.
Using product past its BUD
Premixed bags and compounded vials carry short dating compared with manufactured drugs. Rotate stock and remove expired items weekly.
Grey-market resellers
Buying 503B products from a third party that repackages or resells them can break section 503B conditions. Buy direct or confirm the channel with counsel.
Run your state’s compliance and margin model
Pick your state, licence, model and volume to see the required entity structure, medical director retainer, GFE and 503B supply costs, and net margin, then get matched with the network.
State rules that matter most here
Frequently asked questions
What is the difference between a 503A and a 503B pharmacy?
A 503A pharmacy compounds for individual patients on valid prescriptions and is regulated mainly by its state board. A 503B outsourcing facility registers with FDA, follows cGMP and can supply clinics with office stock without patient names.
Can an IV clinic keep 503A compounded vials in stock?
Under federal law, 503A products are compounded for identified patients, so pooling them into general inventory is not permitted. Some states allow limited office-use compounding under state law, which counsel should review.
How do I verify a 503B outsourcing facility?
Check FDA’s list of registered outsourcing facilities, search for Form 483s, warning letters and recalls, and confirm any state licence required to ship to you. Then request certificates of analysis for the products you plan to buy.
What tests should a CoA show for an IV product?
At minimum, identity and potency, sterility and bacterial endotoxins, with methods and numeric results where applicable. The lot number and BUD on the CoA should match the product you received.
Is NAD+ legal to compound for IV use?
Its status depends on how FDA has categorized the bulk substance under sections 503A and 503B, which has been under review. Confirm current status with your supplier and counsel before you add it to your menu.
Are premixed 503B bags worth the cost?
For multi-ingredient drips they usually are, because preparing those formulas in the clinic would exceed USP <797> immediate-use limits. They also come with release testing and labeled dating that clinic preparations lack.
Sources & standards reviewed
- Federal Food, Drug, and Cosmetic Act sections 503A and 503B U.S. Food and Drug Administration
- Drug Quality and Security Act (2013), Title I: Compounding Quality Act U.S. Congress
- Registered outsourcing facilities list and compounding warning letters U.S. Food and Drug Administration
- USP General Chapters <71> Sterility Tests and <85> Bacterial Endotoxins Test United States Pharmacopeia
- USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations United States Pharmacopeia
Reviewed under the IVConnection clinical and regulatory review policy. Report a correction to clinical@ivconnection.com.